Navigation Links
Umbilical cord cells outperform bone marrow cells in repairing damaged hearts
Date:11/15/2012

TORONTO, Ontario (13 November, 2012) - A study published this month by researchers at the University of Toronto and Toronto's Princess Margaret Hospital has shown that cells derived from the umbilical cord, "Human Umbilical Cord PeriVascular Cells" (HUCPVCs), are more effective in restoring heart function after an acute myocardial infarction (in common parlance, a heart attack) in a pre-clinical model than a similar cell population derived from bone marrow.

At present, mesenchymal cells, known to release a series of factors that stimulate tissue repair, and control inflammation, are most commonly harvested from bone marrow. But the new study, headed by Dr. Armand Keating, now suggests that umbilical cord cells outperform bone marrow cells in improving heart muscle function.

The study, released in Cell Transplantation this month, demonstrates that the cells originating from the tissues surrounding the blood vessels of the human umbilical cord, also known as "Wharton's Jelly," outperformed the current gold standard for stem cell therapies for repairing damage to heart muscles, after an induced heart attack when injected directly into the affected area. Dr. Keating calls the HUCPVC results "statistically and significantly better" than bone marrow cells.

Standard heart function tests measured the effect of the therapy after the cells were injected. The HUCPVC cell therapy was twice as effective at repairing damage to heart tissue than no treatment.

"We are hoping that this translates into fewer people developing complications of heart failure because their muscle function after a heart attack is better," states Keating.

Keating and his team will now complete additional pre-clinical studies, and hope to begin clinical trials of the HUCPVC cells on patients within 12-18 months.

Keating is also interested in conducting further research with the umbilical cord cells to overcome the damaging effects of chemotherapy on heart tissue, an agonizing problem for some patients who may be cured of their cancer only to confront heart failure as a result of treatment.

Apart from heart disease, clinical trials with mesenchymal cells are conducted around the world to investigate the treatment of a variety of diseases, including a serious complication of bone marrow transplantation called graft-versus-host disease, autoimmune disorders, neurological diseases and tissue injury arising from lung and liver disease. Today, more than 250 clinical trials are currently being conducted worldwide using mesenchymal cells.


'/>"/>

Contact: Erin Vollick
comm.ibbme@utoronto.ca
416-946-8019
University of Toronto
Source:Eurekalert  

Related medicine news :

1. Study reveals insights that could aid in therapeutic use of mesenchymal stem cells
2. Smoking affects allergy-relevant stem cells
3. Injectable sponge delivers drugs, cells, and structure
4. How do cells tell time? Scientists develop single-cell imaging to watch the cell clock
5. First trial in humans of minicells: A completely new way of delivering anti-cancer drugs
6. New cells found that could help save peoples sight
7. Spread of human melanoma cells in mice correlates with clinical outcomes in patients
8. Two Years On, Stem Cells Still Healing Damaged Hearts
9. Stem Cells From Donor May Help Heal Heart
10. How bacteria talk to each other and our cells
11. Therapy with bone marrow-derived stem cells does not improve short-term recovery after heart attack
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Umbilical cord cells outperform bone marrow cells in repairing damaged hearts
(Date:6/25/2016)... ... ... The temporary closing of Bruton Memorial Library on June 21 due to a possible lice ... overlooked aspect of head lice: the parasite’s ability to live away from a human host, ... a necessary one in the event that lice have simply gotten out of control. , ...
(Date:6/25/2016)... ... June 25, 2016 , ... First Choice Emergency Room , the ... Ogunleye, as the Medical Director of its new Mesquite-Samuell Farm facility. , “We ... new Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical Director of First Choice ...
(Date:6/25/2016)... Oklahoma (PRWEB) , ... June 25, 2016 , ... ... both athletes and non-athletes recover from injury. Recently, he has implemented orthobiologic procedures ... Oklahoma City area —Johnson is one of the first doctors to perform the ...
(Date:6/25/2016)... Canada (PRWEB) , ... June 25, 2016 , ... Conventional ... pursuit of success. In terms of the latter, setting the bar too high can ... risk more than just slow progress toward their goal. , Research from ...
(Date:6/24/2016)... ... June 24, 2016 , ... Those who have experienced traumatic events may ... to unhealthy avenues, such as drug or alcohol abuse, as a coping mechanism. To ... for healthy coping following a traumatic event. , Trauma sufferers tend to feel a ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... 2016 Research and Markets has announced ... report to their offering. ... a favourable commercial environment for MedImmune to enter. The US ... will serve to drive considerable growth for effective anti-influenza medications. ... cap sales considerably, but development is still in its infancy. ...
(Date:6/23/2016)...  Astellas today announced the establishment of Astellas Farma Colombia (AFC), a new affiliate with operations headquartered in ... . ... ... ... Astellas ...
(Date:6/23/2016)... , June 23, 2016 Research ... "Surgical Procedure Volumes: Global Analysis (United States, China, Japan, ... report to their offering. ... tool for healthcare business planners, provides surgical procedure volume ... surgery trends with an in-depth analysis of growth drivers ...
Breaking Medicine Technology: